Olav Dalgård

14.0k total citations · 2 hit papers
95 papers, 4.9k citations indexed

About

Olav Dalgård is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Olav Dalgård has authored 95 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Hepatology, 78 papers in Epidemiology and 6 papers in Infectious Diseases. Recurrent topics in Olav Dalgård's work include Hepatitis C virus research (86 papers), Liver Disease Diagnosis and Treatment (59 papers) and Hepatitis B Virus Studies (56 papers). Olav Dalgård is often cited by papers focused on Hepatitis C virus research (86 papers), Liver Disease Diagnosis and Treatment (59 papers) and Hepatitis B Virus Studies (56 papers). Olav Dalgård collaborates with scholars based in Norway, Sweden and Denmark. Olav Dalgård's co-authors include Alessio Aghemo, Massimo Puoti, Geoffrey Dusheiko, Francesco Negro, Marina Berenguer, Jean–Michel Pawlotsky, Heiner Wedemeyer, Kjell Skaug, Kristian Bjøro and Kjell B. Hellum and has published in prestigious journals such as Nature Communications, Gastroenterology and PLoS ONE.

In The Last Decade

Olav Dalgård

87 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EASL Recommendations on Treatment of Hepatitis C 2018

2018 1.5k citations Jean–Michel Pawlotsky, Francesco Negro et al. Journal of Hepatology profile →
EASL recommendations on treatment of hepatitis C: Final update of the series☆

2020 707 citations Jean–Michel Pawlotsky, Francesco Negro et al. Journal of Hepatology profile →

Peers

Countries citing papers authored by Olav Dalgård

Since Specialization

Citations

This map shows the geographic impact of Olav Dalgård's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olav Dalgård with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olav Dalgård more than expected).

Fields of papers citing papers by Olav Dalgård

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olav Dalgård. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olav Dalgård. The network helps show where Olav Dalgård may publish in the future.

Co-authorship network of co-authors of Olav Dalgård

This figure shows the co-authorship network connecting the top 25 collaborators of Olav Dalgård. A scholar is included among the top collaborators of Olav Dalgård based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olav Dalgård. Olav Dalgård is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Changes in hepatitis C virus prevalence and incidence among people who inject drugs in the direct acting antiviral era 2024 ·International Journal of Drug Policy ·(unknown), (unknown), Anna Warnqvist, Olav Dalgård, Soo Aleman, Martin Kåberg	4
2	Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines 2023 ·Scientific Reports ·(unknown), Hans Christian D. Aass, Olav Dalgård, (unknown), Dan Sun, Niklas K. Björkström, Asgeir Johannessen, Dag Henrik Reikvam	0
3	Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study 2023 ·International Journal of Drug Policy ·(unknown), (unknown), Ane‐Kristine Finbråten, (unknown), Knut Boe Kielland, (unknown), Olav Dalgård, Håvard Midgard	5
4	Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection 2022 ·Journal of Addictive Diseases ·Olav Dalgård, Alain H. Litwin, Oren Shibolet, Jason Grebely, Ronald Nahass, Frederick L. Altice, Brian Conway, Edward Gane, Anne F. Luetkemeyer, Cheng‐Yuan Peng, David Iser, Isaias Noel Gendrano, (unknown), Barbara Haber, Heather Platt, Amy Puenpatom	3
5	EASL recommendations on treatment of hepatitis C: Final update of the series☆ breakdown → 2020 ·Journal of Hepatology ·Jean–Michel Pawlotsky, Francesco Negro, Alessio Aghemo, Marina Berenguer, Olav Dalgård, Geoffrey Dusheiko, (unknown), Massimo Puoti, Heiner Wedemeyer	707
6	Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs 2020 ·Trials ·Håvard Midgard, Ane‐Kristine Finbråten, (unknown), (unknown), Lars Tanum, Inge Christoffer Olsen, (unknown), Olav Dalgård	6
7	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis 2019 ·Journal of Hepatology ·Behzad Hajarizadeh, Evan B. Cunningham, Heather Valerio, Marianne Martinello, Matthew Law, Naveed Z. Janjua, Håvard Midgard, Olav Dalgård, John Dillon, Matthew Hickman, Julie Bruneau, Gregory J. Dore, Jason Grebely	114
8	Feasibility of reaching world health organization targets for hepatitis C and the cost‐effectiveness of alternative strategies 2018 ·Journal of Viral Hepatitis ·Torbjørn Wisløff, Richard White, Olav Dalgård, Ellen J. Amundsen, Hinta Meijerink, Hilde Kløvstad	6
9	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework 2018 ·Liver International ·(unknown), Margaret Hellard, Carla Treloar, Julie Bruneau, Natasha K. Martin, Anne Øvrehus, Olav Dalgård, Andrew R. Lloyd, John Dillon, Matthew Hickman, Jude Byrne, Alain H. Litwin, Mojca Matičič, Philip Bruggmann, Håvard Midgard, Brianna L. Norton, Stacey Trooskin, Jeffrey V. Lazarus, Jason Grebely, (unknown)	83
10	Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway 2018 ·PharmacoEconomics ·Torbjørn Wisløff, Richard White, Olav Dalgård, Ellen J. Amundsen, Hinta Meijerink, (unknown), Hilde Kløvstad	10
11	Increased hope following successful treatment for hepatitis C infection 2017 ·Journal of Advanced Nursing ·(unknown), Olav Dalgård, Håvard Midgard, Hans Verbaan, Milada Cvancarova Småstuen, Tone Rustøen	2
12	HCV epidemiology in high-risk groups and the risk of reinfection 2016 ·Journal of Hepatology ·Håvard Midgard, Amanda Weir, Norah Palmateer, Vincent Lo Re, Juan A. Pineda, Juan Macı́as, Olav Dalgård	125
13	Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: A longitudinal long-term cohort study 2013 ·Journal of Hepatology ·Knut Boe Kielland, Gerd Jorunn Møller Delaveris, Sidsel Rogde, Tor J. Eide, Ellen J. Amundsen, Olav Dalgård	20
14	Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs 2013 ·Clinical Infectious Diseases ·Geert Robaeys, Jason Grebely, Stefan Mauss, Philip Bruggmann, J. Moussalli, Andrea De Gottardi, Tracy Swan, (unknown), Achim Kautz, Heino Stöver, Heiner Wedemeyer, Martin Schaefer, Lynn E. Taylor, Markus Backmund, Olav Dalgård, Maria Prins, Gregory J. Dore, (unknown)	86
15	IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection 2011 ·Research at the University of Copenhagen (University of Copenhagen) ·Amir Moghaddam, Espen Melum, Nils Reinton, (unknown), Hans Verbaan, Kristian Bjøro, Olav Dalgård	6
16	Il28B Genetic Variation And Treatment Response In Patients With Hcv Genotype 3 Infection 2010 ·Hepatology ·Olav Dalgård, Amir Moghaddam, Hans Verbaan, Helmer Ring‐Larsen, Kristian Bjøro, Espen Melum	4
17	Health-related quality of life in patients with different stages of liver disease induced by hepatitis C 2009 ·Scandinavian Journal of Gastroenterology ·Einar Björnsson, Hans Verbaan, Antti Oksanen, Aril Frydén, Jonas Johansson, (unknown), Olav Dalgård, Evangelos Kalaitzakis	52
18	IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION AND RVR 14 WEEKS TREATMENT IS NON-INFERIOR TO 24 WEEKS. POOLED ANALYSIS OF TWO SCANDINAVIAN TRIALS 2008 ·Hepatology ·Olav Dalgård, Hans Verbaan, Helmer Ring‐Larsen, Kristian Bjøro	2
19	Treatment With Pegylated Interferon and Ribavarin in Hcv Infection With Genotype 2 Or 3 for 14 Weeks: A Pilot Study 2004 ·Hepatology ·Olav Dalgård, Kristian Bjøro, Kjell B. Hellum, Bjørn Myrvang, S Ritland, Kjell Skaug, N Raknerud, Helge Bell	240
20	Behandling ved kronisk hepatitt C 2002 ·Tidsskrift for Den Norske Laegeforening ·Helge Bell, Olav Dalgård, Kristian Bjøro, Kjell B. Hellum, Bjørn Myrvang	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact